Seres Therapeutics Announces Vowst Preliminary Net Sales Of Approximately $10.4M (Unaudited) For Q4 Of 2023, Total 2023 Net Sales Since Launch In June Were Approximately $19.6M And Reflected A Gross-to-net Reduction Of 13%
Portfolio Pulse from Benzinga Newsdesk
Seres Therapeutics reported preliminary unaudited net sales of $10.4M for Q4 2023, with total net sales of $19.6M since the June 2023 launch of Vowst. The sales figures reflect a gross-to-net reduction of 13%. The company saw significant adoption of Vowst, with 2,833 patient enrollment forms received and 2,015 new patient starts by the end of 2023.

January 09, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Seres Therapeutics (MCRB) announced strong preliminary Q4 2023 sales for Vowst, with significant patient adoption since its launch.
The reported preliminary net sales for Q4 and the total sales since the launch of Vowst are likely to be viewed positively by investors, indicating strong market adoption and revenue growth for Seres Therapeutics. The gross-to-net reduction is a common occurrence in the pharmaceutical industry and is unlikely to overshadow the positive sales figures. The high number of patient enrollments and new patient starts further supports the potential for continued growth, which could lead to a positive short-term impact on MCRB's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100